LSF Inhibitor Small Molecules for Hepatocellular Carcinoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatocellular carcinoma (HCC) are inadequate, with limited effective options beyond sorafenib, which offers only marginal survival benefits, and there is a need for novel targeted therapies due to the aggressive nature and poor prognosis of HCC, particularly in cases of metastasis.
Innovation Solution
Development of small-molecule compounds that inhibit the expression of the Late SV40 Factor (LSF) transcription factor, which is highly upregulated in HCC cells, to disrupt oncogenesis and tumor progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (sorafenib) are used for hepatocellular carcinoma, then treatment can be provided, but survival benefits are only marginal and treatment options are limited
Solution Approach 1:
The patent changes the molecular target parameter from conventional kinase inhibition (sorafenib) to transcription factor inhibition (LSF). By identifying and inhibiting LSF, a master transcription factor that regulates multiple oncogenic pathways, the treatment mechanism is fundamentally altered to achieve superior anti-tumor efficacy where conventional therapies have failed
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that specifically bind to and inhibit LSF. These compounds act as mediators between the therapeutic goal (cancer treatment) and the molecular target (LSF), enabling selective inhibition of this transcription factor and its downstream oncogenic pathways without affecting other cellular processes
2Speed
If HCC treatment is delayed or ineffective, then tumor progresses aggressively, but available therapies provide poor prognosis particularly in metastatic cases
Solution Approach 1:
The patent employs preliminary action by inhibiting LSF, a master transcription factor that controls the expression of multiple genes involved in tumor progression and metastasis. By blocking LSF upstream in the regulatory cascade, the patent prevents the activation of downstream oncogenic pathways before they can drive aggressive tumor behavior and metastatic spread
Solution Approach 2:
The patent segments the complex oncogenic network into manageable therapeutic targets by identifying LSF as a key regulatory node. By specifically inhibiting LSF rather than attempting to block multiple downstream effectors simultaneously, the treatment approach simplifies the therapeutic strategy while achieving comprehensive suppression of tumor progression pathways
Data Source
AI summary
The present invention relates generally to methods, compounds and/or compositions suitable for inhibiting, preventing and/or treating cancer, e.g. hepatocellular carcinoma (HCC). In some embodiments, the invention relates to the use of small-molecule compounds to inhibit, prevent and/or treat expression of the transcription factor Late SV40 Factor (LSF) for treatment of HCC or other cancer types.